GlassScriptPhysician profile
Amarinder Singh Garcha
NPI 1770817744
$1,334.51
in general payments reported to CMS, 2019-2025
15 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $165 · 2021: $316 · 2022: $74.18 · 2023: $79.87 · 2024: $18.15 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $429.32 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $264.64 | 2019-2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $126.03 | 2019 | |
| Amgen INC. | $123.53 | 2019-2023 | Parsabiv |
| Vifor Pharma, INC. | $73.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $67.40 | 2020 | |
| Horizon Therapeutics Plc | $47.55 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $42.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.02 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.21 | 2021 | |
| Shire North American Group INC | $23.04 | 2019 | |
| Argon Medical Devices, INC. | $20.59 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.45 | 2019 | |
| Opko Pharmaceuticals, LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarinder Garcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.